Recombinant activated factor VII in the treatment of XXXX and for the prevention of surgery-related @entity548 in @entity447 with inhibitors.

@entity1 @entity1317 @entity548 @entity447
The availability of recombinant activated factor VII (rFVIIa, eptacog alfa activated) has greatly advanced the care of @entity1 with @entity447 or B who have developed inhibitors against the infused replacement factor. Recombinant FVIIa is licensed for the on-demand treatment of @entity548 episodes and the prevention of @entity548 in surgery or invasive procedures in @entity1 with @entity447 with inhibitors. This article attempts to review in detail the extensive evidence of rFVIIa in @entity447 @entity1 with inhibitors. @entity1 with @entity548 are best treated on demand at home, to achieve the short- and long-term benefits of rapid bleed control. Key prospective studies have shown that rFVIIa achieves consistently high efficacy rates in the management of acute (including joint) @entity548 in inhibitor @entity1 in the home treatment setting. Substantial post-approval data from key registries also support the on-demand efficacy profile of rFVIIa established by the prospective clinical trials. The availability of rFVIIa has allowed major surgery to become a reality for inhibitor @entity1 . Studies in key surgery, including orthopaedic procedures, have found that rFVIIa provides consistently high efficacy rates. Importantly, the wealth of data does not raise any unexpected safety concerns surrounding rFVIIa use; this is likely because rFVIIa is a recombinant product with a localised mechanism of action at the site of @entity1317 . In summary, rFVIIa is established as an effective and well-tolerated first-line treatment for on-demand @entity548 control and bleed prevention during minor and major (including elective orthopaedic) surgery in inhibitor @entity1 . Use of rFVIIa has been a major step towards narrowing the gap in outcomes between inhibitor @entity1 and non-inhibitor @entity1 .
